These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33714073)

  • 1. Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis.
    Barkas F; Ntekouan SF; Liberopoulos E; Filippatos T; Milionis H
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105708. PubMed ID: 33714073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
    Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
    Real J; Vlacho B; Ortega E; Vallés JA; Mata-Cases M; Castelblanco E; Wittbrodt ET; Fenici P; Kosiborod M; Mauricio D; Franch-Nadal J
    Cardiovasc Diabetol; 2021 Jul; 20(1):139. PubMed ID: 34243779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
    Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
    Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
    Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tsai WH; Chuang SM; Liu SC; Lee CC; Chien MN; Leung CH; Liu SJ; Shih HM
    Sci Rep; 2021 Jul; 11(1):15364. PubMed ID: 34321571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
    Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
    Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
    Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
    Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
    Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
    Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2i: beyond the glucose-lowering effect.
    Ni L; Yuan C; Chen G; Zhang C; Wu X
    Cardiovasc Diabetol; 2020 Jun; 19(1):98. PubMed ID: 32590982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
    Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
    Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.